摘要:
The present invention relates to the use of dronedarone or a pharmaceutically acceptable salt thereof for the preparation of a drug for the prevention of atrial fibrillation wherein said use comprises the following precaution of use steps: a) initiating dronedarone administration in patients with atrial fibrillation or atrial flutter, b) performing electrocardiograms serially.
摘要:
Methods of using dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality, articles of manufacture and packages related thereto.
摘要:
Methods of using dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality, articles of manufacture and packages related thereto.
摘要:
The disclosure relates to a combination of dronedarone or a pharmaceutically salt thereof with at least one diuretic, and to the therapeutic use thereof.
摘要:
The present invention concerns the use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the prevention and/or treatment of patients with atrial fibrillation (AF) or atrial Flutter (AFL), shortly after discontinuation of a previous treatment with amiodarone.
摘要:
The disclosure relates to a method for managing the risk of dronedarone/calcium channel blockers interaction by using dronedarone or pharmaceutically acceptable salts thereof in patients with paroxysmal or persistent atrial fibrillation (AF) or atrial flutter (AFL), with a recent episode of AF/AFL and associated cardiovascular risk factors, who are in sinus rhythm or who will be cardioverted to reduce the risk of cardiovascular hospitalization, said patients also expecting to receive a calcium channel blockers treatment, by performing the following steps: a—initiate calcium channel blockers treatment at a low dose; b—performing a electrocardiogram (ECG) verification of good tolerability; c—increase of calcium channel blockers dose only if results in step b) are satisfying.
摘要:
The invention relates to a method of reducing occurrences of cardiovascular hospitalization of a patient by administering to the patient a pharmaceutically effective dose of the compound celivarone, or a pharmaceutically acceptable salt thereof.